Astex Pharma Announces It Will Halt Development of Lung Cancer Drug

by Kathy Jones on  September 22, 2012 at 8:36 PM Corporate News
RSS Email Print This Page Comment
Font : A-A+

Astex Pharmaceuticals Inc has confirmed that it will be halting the development of experimental small-cell lung cancer drug, Amuvatinib. The reason is that the drug failed to achieve a high response rate on an ongoing study.
 Astex Pharma Announces It Will Halt Development of Lung Cancer Drug
Astex Pharma Announces It Will Halt Development of Lung Cancer Drug

The main goal of the trial, known as ESCAPE, was to evaluate if the drug achieved a response rate of 10 percent. However Amuvatinib was able to achieve a rate of only 9.5 percent.

The company said in a statement that no new safety issues were identified during the trial and that it would license the drug to any other companies interested in developing it further.



Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Lung Biopsy Lung Cancer Malignant Mesothelioma Cancer and Homeopathy Signature Drug Toxicity Cancer Facts Asbestosis Cancer Tattoos A Body Art 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive